Filtered By:
Infectious Disease: COVID-19
Vaccination: Cancer Vaccines
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 1918 results found since Jan 2013.
Biomaterial-based delivery platforms for transdermal immunotherapy
Biomed Pharmacother. 2023 Jun 27;165:115048. doi: 10.1016/j.biopha.2023.115048. Online ahead of print.ABSTRACTNowadays, immunotherapy is one of the most essential treatments for various diseases and a broad spectrum of disorders are assumed to be treated by altering the function of the immune system. For this reason, immunotherapy has attracted a great deal of attention and numerous studies on different approaches for immunotherapies have been investigated, using multiple biomaterials and carriers, from nanoparticles (NPs) to microneedles (MNs). In this review, the immunotherapy strategies, biomaterials, devices, and disea...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - June 29, 2023 Category: Drugs & Pharmacology Authors: Mohammad Dahri Nima Beheshtizadeh Nasrin Seyedpour Amin Nakhostin-Ansari Faezeh Aghajani Simin Seyedpour Moein Masjedi Fatemeh Farjadian Reza Maleki Khosro Adibkia Source Type: research
Anthracyclines inhibit SARS-CoV-2 infection
Virus Res. 2023 Jun 26:199164. doi: 10.1016/j.virusres.2023.199164. Online ahead of print.ABSTRACTVaccines and drugs are two effective medical interventions to mitigate SARS-CoV-2 infection. Three SARS-CoV-2 inhibitors, remdesivir, paxlovid, and molnupiravir, have been approved for treating COVID-19 patients, but more are needed, because each drug has its limitation of usage and SARS-CoV-2 constantly develops drug resistance mutations. In addition, SARS-CoV-2 drugs have the potential to be repurposed to inhibit new human coronaviruses, thus help to prepare for future coronavirus outbreaks. We have screened a library of mic...
Source: Virus Research - June 28, 2023 Category: Virology Authors: Zhen Wang Qinghua Pan Ling Ma Jianyuan Zhao Fiona McIntosh Zhenlong Liu Shilei Ding Rongtuan Lin Shan Chen Andr és Finzi Chen Liang Source Type: research
Advances in mRNA Therapeutics for Cancer Immunotherapy: From Modification to Delivery
Adv Drug Deliv Rev. 2023 Jun 25:114973. doi: 10.1016/j.addr.2023.114973. Online ahead of print.ABSTRACTRNA vaccines have demonstrated their ability to solve the issues posed by the COVID-19 pandemic. This success has led to the renaissance of research into mRNA and their nanoformulations as potential therapeutic modalities for various diseases. The potential of mRNA as a template for synthesizing proteins and protein fragments for cancer immunotherapy is now being explored. Despite the promise, the use of mRNA in cancer immunotherapy is limited by challenges, such as low stability against extracellular RNases, poor deliver...
Source: Advanced Drug Delivery Reviews - June 27, 2023 Category: Drugs & Pharmacology Authors: Geonhee Han Dahye Noh Hokyung Lee Sangmin Lee Sehoon Kim Hong Yeol Yoon Soo Hyeon Lee Source Type: research
Epidemiological study of vaccination against SARS-CoV-2 and its impact on COVID-19 progression in a cohort of patients in gran Canaria
Conclusions. Cancer, coronary heart disease, and immunosuppressive treatment were associated with increased COVID-19 mortality. More complete vaccination was associated with lower risk of hospital admission or death. Three doses of the SARS-CoV-2 vaccine were highly associated with the prevention of death and hospital admission in all age groups. These findings suggest that COVID-19 vaccination can help bring the pandemic under control.PMID:37366493 | PMC:PMC10288311 | DOI:10.1016/j.vacun.2023.06.005
Source: Cancer Control - June 27, 2023 Category: Cancer & Oncology Authors: Alejandro de Arriba Fern ández Jos é Luis Alonso Bilbao Alberto Espi ñeira Francés Antonio Cabeza Mora Ángela Gutiérrez Pérez Miguel Ángel Díaz Barreiros Source Type: research
Fight Aging! Newsletter, June 26th 2023
This study explored the association between different cooking fuel types and the risk of cancer and all-cause mortality among seniors constructing Cox regression models. Data were obtained by linking waves of 6, 7, and 8 of the Chinese Longitudinal Healthy Longevity Survey, which included a total of 7,269 participants who were 65 years old and over. Cooking fuels were categorized as either biomass, fossil, or clean fuels. And the effects of switching cooking fuels on death risk were also investigated using Cox regression models.
The results indicate that, compared with the users of clean fuels, individuals using bio...
Source: Fight Aging! - June 25, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Data quality in an HIV vaccine efficacy clinical trial in South Africa: through natural disasters and with discipline
CONCLUSIONS: In the age of infectious and climate disaster risks, trials may benefit from simple study designs and trial-related documents. To optimise protocol adherence, sponsors and sites should consider ongoing training, and routinely review deviation reports with a view to adjusting processes. These data quality lessons may inform future trial design, training and implementation.TRIAL REGISTRATION: HVTN 702 was registered with the South African National Clinical Trials Register (DOH-27-0916-5327) and ClinicalTrials.gov ( NCT02968849 ).PMID:37355583 | DOI:10.1186/s12874-023-01967-9
Source: Cancer Control - June 24, 2023 Category: Cancer & Oncology Authors: Fatima Laher Mookho Malahleha Shelly Ramirez William Brumskine Kennedy Otwombe Zoe Moodie Mary Allen Source Type: research
Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial
Lancet Microbe. 2023 Jun 21:S2666-5247(23)00107-6. doi: 10.1016/S2666-5247(23)00107-6. Online ahead of print.ABSTRACTBACKGROUND: Correlates of protection could help to assess the extent to which a person is protected from SARS-CoV-2 infection after vaccination (so-called breakthrough infection). We aimed to clarify associations of antibody and T-cell responses after vaccination against COVID-19 with risk of a SARS-CoV-2 breakthrough infection and whether measurement of these responses enhances risk prediction.METHODS: We did an open-label, phase 4 trial in two community centres in the Schwaz district of the Federal State o...
Source: Cancer Control - June 24, 2023 Category: Cancer & Oncology Authors: Lisa Seekircher Zolt án Bánki Janine Kimpel Annika R össler Helena Sch äfer Barbara Falkensammer David Bante Lukas Forer Sebastian Sch önherr Shieldvacc-2 Study Group Teresa Harthaller Magdalena Sacher Cornelia Ower Lena Tschiderer Hanno Ulmer Floria Source Type: research
COVID-19 vaccination effectiveness and safety in vulnerable populations: a meta-analysis of 33 observational studies
Conclusion: Seroconversion rates after COVID-19 vaccination were generally worse in the vulnerable than healthy populations, but there was no difference in adverse events. Patients with hematological cancers had the lowest IgG antibody levels of all the vulnerable populations, so closer attention to these patients is recommended. Subjects who received the combined vaccine had higher antibody levels than those who received the single vaccine.
Source: Frontiers in Pharmacology - June 23, 2023 Category: Drugs & Pharmacology Source Type: research
Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients
Haematologica. 2023 Jun 22. doi: 10.3324/haematol.2023.283015. Online ahead of print.ABSTRACTAZD7442 (tixagevimab-cilgavimab) is a combination of two human monoclonal antibodies for preexposure prophylaxis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among highrisk patients who do not mount a reliable vaccine response. Foremost among these are hematologic malignancy patients with limited clinical trial or real-world experience to assess the effectiveness of this combination treatment since the emergence of Omicron and its subvariants. We performed a retrospective study of 892 highrisk hematolog...
Source: Haematologica - June 22, 2023 Category: Hematology Authors: Justin C Laracy Judy Yan Samantha N Steiger Carrie A Tan Nina Cohen Elizabeth V Robilotti Jerome Fender Sara Cohen Neha Korde Melissa Lee-Teh Ariela Noy Joseph H Oved Lindsey E Roeker Gunjan Shah N Esther Babady Mini Kamboj Susan K Seo Source Type: research
